Late-breaking Presentation for the Clinical Trial Compares Aquablation to Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (BPH)
REDWOOD SHORES, Calif. – May 3, 2017 – PROCEPT BioRobotics, a Silicon Valley robotics company developing intelligent surgical solutions to treat prostate disease, announced today that primary endpoint results of the global Phase III WATER Study (Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue) of its Aquablation technology will be presented in a late-breaking clinical trial session at the American Urological Association (AUA) Annual Meeting in Boston, May 12 – 15, 2017. Aquablation, delivered by PROCEPT BioRobotics’ AQUABEAM® System, uses a robotically controlled waterjet to remove prostate tissue without application of heat.
The presentation, titled, “The WATER Study Clinical Results – A Phase III blinded randomized parallel group trial of Aquablation vs. Transurethral Resection of the Prostate with Blinded Outcome Assessment for Moderate-to-Severe LUTS in men with BPH,” will be given by Claus Roehrborn, MD, chair of the Department of Urology at UT Southwestern in Dallas, Texas, during the plenary session, “Next Frontier,” on Sunday, May 14 at 1:05 pm EST in Ballroom East.
Adding to the Aquablation study data to be shared at the meeting, Professor Peter Gilling, co-principal investigator of the WATER Study and professor of surgery at the University of Auckland, Bay of Plenty Clinical School Tauranga, New Zealand, will also be presenting longer-term results from the Phase II trial during a presentation titled, “Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Two-Year Results,” on Saturday, May 13 at 11:10 am EST in Room 162.
“We are thrilled to be able to present the primary endpoint results of the WATER IDE study just two years after initial submission of the trial protocol to the U.S. Food and Drug Administration,” said Nikolai Aljuri, Ph.D, co-founder and chief executive officer at PROCEPT BioRobotics. “We believe that these important data, along with the two-year results from our Phase II study, represent a growing body of evidence designed to support the safety and efficacy of Aquablation. Together, these studies are critical to achieving our goal of bettering the lives of men suffering from BPH by developing a minimally invasive solution that offers both a sustained and significant improvement to quality of life, and a reduced risk of sexual side effects.”
For more information about the AQUABEAM System and Aquablation, visit PROCEPT BioRobotics at AUA booth #2235.
About the AQUABEAM System and Aquablation
The AQUABEAM System is the only surgical device for Benign Prostatic Hyperplasia (BPH) that combines intra-procedural ultrasound imaging and surgical robotics to deliver Aquablation, a waterjet ablation technology that enables targeted, controlled, heat-free and immediate removal of prostate tissue for the treatment of lower urinary tract symptoms caused by BPH. By combining traditional cystoscopic visualization with ultrasound imaging, the AQUABEAM System provides a real-time multi-dimensional view of the prostate, empowering the surgeon with improved decision making during the procedure.
Prior to resection, the surgeon uses the AQUABEAM software to clearly define the area of resection while sparing the anatomical landmarks responsible for continence, erectile, and ejaculatory function. The robotically controlled waterjet then resects the tissue according to the prescribed treatment plan. The combination of surgical mapping and controlled resection of the prostate is designed to offer predictable and reproducible outcomes, independent of prostate size and shape. In the U.S., the AQUABEAM System is available for investigational use only. The AQUABEAM System has CE Mark approval, TGA and MedSafe registration and is now available in select global markets.
About PROCEPT BioRobotics
Based in Silicon Valley, PROCEPT BioRobotics is bettering the lives of men by developing robotic surgical solutions to treat prostate disease. With an initial focus on benign prostatic hyperplasia (BPH), the company has developed the AQUABEAM System, which leverages Aquablation, the company’s core technology platform. Aquablation technology uses robotics to control a waterjet that enables targeted, heat-free and immediate removal of prostate tissue.